The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Scott A Flanders - One of the best experts on this subject based on the ideXlab platform.

  • empiric Antibacterial Therapy and community onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2021
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

  • empiric Antibacterial Therapy and community onset bacterial co infection in patients hospitalized with covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2020
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

Valerie M Vaughn - One of the best experts on this subject based on the ideXlab platform.

  • empiric Antibacterial Therapy and community onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2021
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

  • empiric Antibacterial Therapy and community onset bacterial co infection in patients hospitalized with covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2020
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

Payal K Patel - One of the best experts on this subject based on the ideXlab platform.

  • empiric Antibacterial Therapy and community onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2021
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

  • empiric Antibacterial Therapy and community onset bacterial co infection in patients hospitalized with covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2020
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

Tejal N Gandhi - One of the best experts on this subject based on the ideXlab platform.

  • empiric Antibacterial Therapy and community onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2021
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

  • empiric Antibacterial Therapy and community onset bacterial co infection in patients hospitalized with covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2020
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

Lindsay A Petty - One of the best experts on this subject based on the ideXlab platform.

  • empiric Antibacterial Therapy and community onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2021
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.

  • empiric Antibacterial Therapy and community onset bacterial co infection in patients hospitalized with covid 19 a multi hospital cohort study
    Clinical Infectious Diseases, 2020
    Co-Authors: Valerie M Vaughn, Tejal N Gandhi, Lindsay A Petty, Payal K Patel, Hallie C Prescott, Anurag N Malani, David Ratz, Elizabeth Mclaughlin, Vineet Chopra, Scott A Flanders
    Abstract:

    BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric Antibacterial Therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric Antibacterial Therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric Antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric Antibacterial Therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric Antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric Antibacterial Therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m 2), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric Antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric Antibacterial Therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve Antibacterial use.